Pfizer was already expecting lower revenues from Paxlovid before the company amended its agreement with the U.S. government. The pharmaceutical company says it expects $7 billion less in revenue from Paxlovid for 2023 compared with prior guidance as it accepts unused doses of the anti-viral pill from the government and reverses associated revenues. The company was already forecasting Paxlovid revenues to drop 58% in 2023 to $8 billion, part of a broader slowdown in its Covid-19 business.